Pharma Report on Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/human-papillomavirus-hpv-associated-cancer-pipeline-review-h2-2020-645857.html

Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2020

Summary

Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2020, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 26, 15, 33, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 12 and 2 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Abion Inc
Abivax SA
Advaxis Inc
Anteris Technologies Ltd
Antiva Biosciences Inc
Apimeds Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Avalia Immunotherapies Ltd
Beijing Recreation Guards Biotechnology Co Ltd
BioMed Valley Discoveries Inc
Biond Biologics Ltd
BioNTech SE
Blue Sky Immunotherapies GmbH
Cellid Co Ltd
Chain Biotechnology Ltd
Chengdu Institute of Biological Products Co Ltd
Cue Biopharma Inc
Cullinan Oncology LLC
Elicio Therapeutics
Etubics Corp
EyeGene Inc
Genexine Inc
Gilead Sciences Inc
Hookipa Pharma Inc
iBio Inc
Immunomic Therapeutics Inc
IMV Inc
Innovene
Inovio Pharmaceuticals Inc
Inthera Bioscience AG
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Ispin Inc
Johnson & Johnson
Juno Therapeutics Inc
Merck KGaA
OncoNano Medicine Inc
Onconova Therapeutics Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Pathovax LLC
Pattern Pharma Inc
PDS Biotechnology Corp
Precigen Inc
Privo Technologies Inc
Profectus BioSciences Inc
Rottapharm Biotech Srl
Rubius Therapeutics Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shantha Biotechnics Pvt Ltd
Shuttle Pharmaceuticals Inc
TCR Cure Biopharma Technology Co Ltd
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Touchlight Genetics Ltd
Transgene SA
Turnstone Biologics Inc
UbiVac LLC
Vaccibody AS
Vault Pharma Inc
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Virion Therapeutics LLC
Virometix AG
VLP The Vaccines Company SL
Voltron Therapeutics Inc
Xiamen Innovax Biotech Co Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645857

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.